Literature DB >> 1934255

Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme.

M Marselos1, H Vainio.   

Abstract

Almost 200 pharmaceutical chemicals and groups of drugs have been evaluated for their carcinogenic properties by working groups convened by the International Agency for the Research on Cancer. Therapeutic agents are exceptional environmental carcinogens in that humans are exposed to relatively pure substances at well-defined dosages. Of those evaluated, 20 are conclusively carcinogenic to humans and 52 are probably or possibly carcinogenic. The human tissues most often affected are bone marrow, skin, urinary bladder, liver, lymphatic tissue and endometrium. In cases in which there is sufficient evidence for carcinogenicity from both epidemiological and experimental studies, the similarity between humans and animals with regard to the target organs involved is close (85%). Since data on carcinogenicity exist for several groups of pharmaceuticals, risk versus benefit evaluations should be made carefully in relation to possible clinical applications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934255     DOI: 10.1093/carcin/12.10.1751

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

Review 1.  Evaluation of the carcinogenic potential of pharmaceuticals. Opportunities arising from the International Conference on Harmonisation.

Authors:  A M Monro; J S MacDonald
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

2.  Mutagenicity of cytostatic drugs in a bacterial system. I. Ames test.

Authors:  J Marhan
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

3.  Pancreatic cancer risk after treatment of Hodgkin lymphoma.

Authors:  G M Dores; R E Curtis; F E van Leeuwen; M Stovall; P Hall; C F Lynch; S A Smith; R E Weathers; H H Storm; D C Hodgson; R A Kleinerman; H Joensuu; T B Johannesen; M Andersson; E J Holowaty; M Kaijser; E Pukkala; L Vaalavirta; S D Fossa; F Langmark; L B Travis; J F Fraumeni; B M Aleman; L M Morton; E S Gilbert
Journal:  Ann Oncol       Date:  2014-07-25       Impact factor: 32.976

Review 4.  In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.

Authors:  J F Contrera; J J DeGeorge
Journal:  Environ Health Perspect       Date:  1998-02       Impact factor: 9.031

5.  Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: technical progress or cycle of regulatory capture?

Authors:  John Abraham; Rachel Ballinger
Journal:  Soc Sci Med       Date:  2012-06-28       Impact factor: 4.634

6.  Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report.

Authors:  Naitielle Pantano; Brady Hunt; Richard A Schwarz; Sonia Parra; Katelin Cherry; Júlio César Possati-Resende; Adhemar Longatto-Filho; José Humberto Tavares Guerreiro Fregnani; Philip E Castle; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  Photochem Photobiol       Date:  2018-07-31       Impact factor: 3.421

7.  Characterization of Miconazole Effects on Mice Fetus Liver Tissue Using FTIR-MSP.

Authors:  Azadeh Ashtarinezhad; Ataollah Panahyab; Baharak Mohamadzadehasl; Farshad H Shirazi
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

8.  Analysis of apoptosis related genes in nurses exposed to anti-neoplastic drugs.

Authors:  Maral Ramazani; Razieh Pourahmad Jaktaji; Farshad H Shirazi; Maria Tavakoli-Ardakani; Ahmad Salimi; Jalal Pourahmad
Journal:  BMC Pharmacol Toxicol       Date:  2019-12-02       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.